Immunoprophylaxis of Infection with Hepatitis B Virus in Infants Born to Hepatitis B Surface Antigen-Positive Carrier Mothers

• Published in: The Journal of infectious diseases Vol. 152; no. 4; pp. 817 - 822
• Main Authors: Lo, Kwang-Juei, Tsai, Yang-Te, Lee, Shou-Dong, Wu, Tzee-Chung, Wang, Jiin-Yu, Chen, Gran-Hum, Yeh, Ching-Lan, Chiang, Benjamin N., Yeh, Shin-Hwa, Goudeau, Alain, Coursaget, Pierre, Tong, Myron J.
• Format: Journal Article
• Language: English
• Published: Chicago, IL The University of Chicago Press 01.10.1985; University of Chicago Press
• Subjects: Adult; Biological and medical sciences; Carrier State; Child, Preschool; Disease transmission; Dosage; Female; Hepatitis; Hepatitis antigens; Hepatitis B; Hepatitis B - congenital; Hepatitis B - prevention & control; Hepatitis B Antibodies - analysis; Hepatitis B e Antigens - analysis; Hepatitis B Surface Antigens - analysis; Hepatitis B Vaccines; Hepatitis B virus; Human viral diseases; Humans; Immunoglobulins; Infant; Infant, Newborn; Infants; Infections; Infectious diseases; Medical sciences; Original Articles; Pregnancy; Pregnancy Complications, Infectious; Vaccination; Viral diseases; Viral hepatitis; Viral Hepatitis Vaccines - immunology; Human; Hepatitis B surface antigen; Vaccination; Infant; Hepatobiliary disease; Infection; Viral hepatitis B; Immunoprophylaxis; Mother; Asia; Viral disease; China; Digestive diseases; Carrier
• ISSN: 0022-1899; 1537-6613
• DOI: 10.1093/infdis/152.4.817

Infants born to carrier mothers positive for hepatitis B surface antigen (HBsAg) and hepatitis Be antigen (HBeAg)received 5 µg of hepatitis B virus (HBV) vaccine on four occasions. Group 1 received vaccine only, group 2 received vaccine plus hepatitis B immune globulin (HBIG)at birth, and group 3 received vaccine plus HBIG at birth and at one month. Infants born to HBeAg-positive mothers (group 4) received a reduced dose of vaccine (2.5 µg) on three occasions as well as HBIG at birth. As compared with 78.4% of the control group (infants whose parents refused vaccination) who became chronic HBV carriers at the age of 14 months, the protective efficacy rate of vaccination was 75.3% in group 1, 85.5% in group 2, 89.7% in group 3, and 87.2% in group 4. HBV vaccine (5 µg) was also given to infants born to HBsAg-positive, HBeAg-negative mothers on four occasions. The antibody response to HBsAg in vaccine recipients was 12% after the first dose, 44% after the second dose, and 75% and 100% at six months and 1.5 years of age, respectively.